MSLN and familial pancreatic carcinoma: They studied PD-1 KO anti-mesothelin CAR T cells in nine patients (six pancreatic, two ovarian, and one colorectal carcinomas) [53], as well as TRAC + PD-1 KO anti-mesothelin CARs in 15 (six pancreatic cancer, three biliary carcinoma, and six other) [254].